On this South by Southwest conference panel, Punit Dhillon and Clinical Advisory Board Member Dr. Beverly Tchang, MD participate in a discussion about the need for improved sustainable weight loss outcomes, emerging scientific advancements, combination therapies, and the possibilities of CB1 inhibition.
CEO Punit Dhillon discusses Skye’s accomplishments in 2024 and the execution plans for 2025, in particular announcing data from its Phase 2 study of nimacimab for weight loss.
New insights from KOLs and management regarding centrally vs peripherally-driven CB1 inhibition, and data from Skye’s diet-induced obesity model highlighting dose-dependent weight loss.
KOL and management insights into the unmet treatment needs related to obesity, and the potential role of CB1 inhibition.